
|Articles|October 1, 2002
PhotoPoint review: Further results found in AMD drug trial Santa Barbara, CA-Miravant Medic
Santa Barbara, CA-Miravant Medical Technologies says 65.6% of patients who were treated three times over 2 years at a lower dose of its PhotoPoint SnET2 photodynamic therapy for wet age-related macular degeneration (AMD) maintained stable vision compared with 39.3% of patients taking placebo.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
2
New optoretinography technique allows direct measurement of rod function in vivo
3
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis
4
Long-lived Greenland sharks may point to new approaches for retinal disease
5












































